Hamieh L, Choueiri TK, Ogórek B, et al. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018;14(9):e1007679. doi:10.1371/journal.pgen.1007679.

Bellmunt J, Lalani A-KA, Jacobus S, et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018;119(6):707-712. doi:10.1038/s41416-018-0261-0.

Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806. doi:10.1126/science.aan5951.

Beckermann KE, Sharma D, Chaturvedi S, et al. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017;13(7):414-421. doi:10.1200/JOP.2017.020909.

Chakraborty AA, Nakamura E, Qi J, et al. HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase. Sci Transl Med. 2017;9(398). doi:10.1126/scitranslmed.aal5272.

Zou Y, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10(1):1617. doi:10.1038/s41467-019-09277-9.

Lalani A-KA, Xie W, Martini DJ, et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5. doi:10.1186/s40425-018-0315-0.

Ricketts CJ, de Cubas AA, Fan H, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018;23(1):313-326.e5. doi:10.1016/j.celrep.2018.03.075.

Gopal RK, Calvo SE, Shih AR, et al. Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. Proc Natl Acad Sci U S A. 2018;115(27):E6283-E6290. doi:10.1073/pnas.1711888115.

Aiden AP, Rivera MN, Rheinbay E, et al. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell. 2010;6(6):591-602. doi:10.1016/j.stem.2010.03.016.